Actively Recruiting
A Study of HS-20122 in Patients With Advanced Solid Tumors
Led by Hansoh BioMedical R&D Company · Updated on 2026-01-16
1050
Participants Needed
1
Research Sites
167 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of HS-20122, in patients with advanced solid tumors. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-20122 in advanced solid tumors.
CONDITIONS
Official Title
A Study of HS-20122 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 years or older
- Histologically or cytologically confirmed locally advanced or metastatic solid tumors
- Standard treatment is invalid, unavailable, or intolerable
- At least one target lesion measurable by RECIST 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Estimated life expectancy greater than 12 weeks
- Use of adequate contraceptive measures throughout the study for men and women
- Women must have evidence of non-childbearing potential
- Signed and dated informed consent form
You will not qualify if you...
- Unresolved toxicities from prior therapy greater than Grade 2 by CTCAE 5.0, except alopecia or neurotoxicity
- History of other primary cancers
- Inadequate bone marrow or organ function
- Evidence of cardiovascular risk
- Severe or poorly controlled diabetes
- Severe or poorly controlled hypertension
- Clinically significant bleeding or bleeding tendency within 1 month prior to first dose
- Severe arteriovenous thrombotic events within 3 months
- Severe infection within 4 weeks prior to first dose
- Steroid therapy longer than 30 days
- Known active infections
- Significant gastrointestinal dysfunction
- Hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis Child-Pugh Grade B or worse
- Moderate to severe pulmonary diseases
- Significant neurological or mental disorders
- Women who are pregnant, breastfeeding, or planning pregnancy during the study
- Hypersensitivity to any ingredient of HS-20122
- Unlikely to comply with study procedures or restrictions as judged by investigator
- Any disease or condition that may compromise safety or interfere with study assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ethics Committee of Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
K
Ketao Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here